Abstract

A pharmaceutical composition according to the present invention contains adenine, carnitine, and cyanocobalamin, and the present invention provides: a pharmaceutical composition capable of ensuring stability of adenine by using a blocker or a blocking structure; and a method for preparing the same. The pharmaceutical composition according to the present invention ensures stability of adenine, so that the content of adenine is maintained at 95% or more after six months in a stability test under acceleration conditions (40±2°C/75±5%RH).

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/50 - Microcapsules
• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine

Abstract

The present invention relates to erlotinib dichloroacetate and an anti-cancer agent comprising the same. The erlotinib dichloroacetate of the present invention can inhibit epidermal growth factor receptor as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid.

IPC Classes  ?

• C07D 239/94 - Nitrogen atoms
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a pharmaceutical composition for treating or preventing type II diabetes mellitus comprising piperazine dithioctate and glimepiride, which is a new combination drug. The pharmaceutical composition of the present invention has strong synergistic effects for treating type II diabetes mellitus by improving metabolic disorders and insulin resistance of diabetic patients as well as lowering blood glucose levels, and by increasing glucose uptake in cells, compared with single treatment of piperazine dithioctate or glimepiride, or combination treatment of thioctic acid and glimepiride.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07D 339/02 - Five-membered rings
• C07D 295/027 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring

Abstract

The present invention relates to acetyl-L-carnitine malate, a process for preparing the same, and a pharmaceutical composition comprising the same. The acetyl-L-carnitine malate of the present invention has good stability, solubility, and non-hygroscopicity to be effectively used for preparing a pharmaceutical composition.

IPC Classes  ?

• C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
• C07C 227/16 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to imatinib dichloroacetate and an anti-cancer agent comprising the same. The imatinib dichloroacetate of the present invention can inhibit tyrosine kinase as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between imatinib and dichloroacetic acid.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to piperazine dithioctate, a novel addition salt of thioctic acid with a base and a pharmaceutical composition comprising the same. The piperazine dithioctate according to the present invention has good thermal and moisture stability and high water-solubility as well as dosage increase lower than other addition salts, thereby being effectively used for preparing a pharmaceutical composition for antioxidation or for preventing or treating diabetic polyneuropathy, etc.

IPC Classes  ?

• C07D 339/02 - Five-membered rings
• C07D 339/00 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms